GLP-1 weight loss drugs aren’t worth their high price tag: A new study gives commercial and government insurers another reason to deny GLP-1 drug coverage.

Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown—and possible price war—between Novo and Lilly.

Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.

The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.

Everyone is talking about Hims’ Super Bowl weight loss drug ad: The reaction has been largely negative. We examine why it’s a gamble that will likely pay off for Hims.

Pharma giants report mixed earnings for GLP-1s in Q4: Supply challenges and weight loss drug market competition could pose the biggest threats to Novo and Lilly in 2025.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what’s at stake for drugmakers and D2C companies selling compounded weight loss medications.

Healthcare and pharma companies are embracing D2C business models to get their medications, treatments, and services to more consumers without industry middlemen restricting access. Concurrently, patients are becoming more price-conscious healthcare shoppers, propelling more D2C activity next year.

Eli Lilly and Ro join forces to offer lower price vials of Zepbound: Seeing competitors become business partners may seem surprising, but we detail why the deal makes sense for both parties.

Hims to offer a generic GLP-1 in 2025: It’s preparing for headwinds if the FDA halts compounded versions of weight loss drugs. But we think its diverse D2C offerings and strong subscriber growth should help insulate it financially.

Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.

Bad actors flood the GLP-1 weight loss drug market: Until the cost of branded GLP-1s drops, illegal online pharmacies advertising falsified versions of the drugs will keep lingering.

Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.

Diabetes drug makers come under gov’t pressure: Big Pharma reacts to Biden administration push for limits on insulin prices. A majority of consumers—and employers—are cheering on cost pressures.